Webster Bank N. A. Sells 2,014 Shares of Johnson & Johnson (NYSE:JNJ)

Webster Bank N. A. lowered its stake in Johnson & Johnson (NYSE:JNJ - Free Report) by 4.1% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,718 shares of the company's stock after selling 2,014 shares during the quarter. Webster Bank N. A.'s holdings in Johnson & Johnson were worth $6,756,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. waypoint wealth counsel raised its holdings in shares of Johnson & Johnson by 4.0% in the 4th quarter. waypoint wealth counsel now owns 5,092 shares of the company's stock worth $736,000 after acquiring an additional 196 shares during the last quarter. Union Bancaire Privee UBP SA bought a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $85,886,000. Apexium Financial LP boosted its position in shares of Johnson & Johnson by 108.1% during the fourth quarter. Apexium Financial LP now owns 21,679 shares of the company's stock valued at $3,135,000 after buying an additional 11,262 shares during the last quarter. Capital Asset Advisory Services LLC raised its position in Johnson & Johnson by 2.1% in the 4th quarter. Capital Asset Advisory Services LLC now owns 30,252 shares of the company's stock valued at $4,362,000 after buying an additional 631 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in Johnson & Johnson by 55.7% during the 4th quarter. Blue Trust Inc. now owns 76,342 shares of the company's stock valued at $11,041,000 after acquiring an additional 27,308 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on JNJ. Raymond James reduced their price objective on shares of Johnson & Johnson from $170.00 to $165.00 and set an "outperform" rating for the company in a research report on Thursday, January 23rd. Barclays lifted their price target on Johnson & Johnson from $159.00 to $166.00 and gave the stock an "equal weight" rating in a report on Tuesday. Stifel Nicolaus decreased their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating for the company in a research report on Thursday, January 23rd. Cantor Fitzgerald restated an "overweight" rating and set a $215.00 price target on shares of Johnson & Johnson in a research report on Wednesday, October 16th. Finally, Guggenheim lifted their price objective on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a "neutral" rating in a research report on Wednesday, November 6th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Johnson & Johnson has a consensus rating of "Moderate Buy" and a consensus price target of $170.44.

Insider Activity

In other news, Director Mark A. Weinberger bought 1,000 shares of the firm's stock in a transaction on Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, with a total value of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares of the company's stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Up 1.1 %

NYSE JNJ traded up $1.63 during trading on Thursday, hitting $152.78. The company had a trading volume of 8,907,293 shares, compared to its average volume of 9,702,731. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company's fifty day moving average is $147.73 and its 200-day moving average is $156.10. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The company has a market cap of $367.82 billion, a price-to-earnings ratio of 22.97, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analysts' expectations of $22.44 billion. During the same period in the prior year, the firm earned $2.29 earnings per share. The firm's revenue for the quarter was up 5.3% on a year-over-year basis. On average, sell-side analysts predict that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.25%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson's dividend payout ratio (DPR) is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.